What is the recommended management for moderate to severe hepatic steatosis?

Management of Moderate to Severe Hepatic Steatosis

For moderate to severe hepatic steatosis (MASLD), initiate lifestyle modification with weight loss and exercise as first-line therapy, and if significant fibrosis (stage F2-F3) is present, consider pharmacotherapy with resmetirom (if locally approved) or semaglutide 2.4 mg weekly, which both demonstrate histological efficacy in reducing steatohepatitis and fibrosis. 1, 2

Lifestyle Modification: Foundation of Treatment

Weight Loss and Dietary Changes

• Target weight reduction through caloric restriction, as this directly reduces hepatic steatosis and improves liver injury 1
• Implement dietary modifications tailored to individual preference, though evidence for specific diet quality improving clinical liver outcomes remains limited 1
• Coffee consumption may provide additional benefit, as observational studies associate it with improvements in liver damage and reduced liver-related clinical outcomes 1

Physical Activity

• Prescribe at least 150 minutes per week of moderate-intensity or 75 minutes per week of vigorous-intensity physical activity to reduce steatosis 1
• This recommendation applies even to normal-weight adults with MASLD, though evidence for histological improvement in this population is lacking 1
• Note that while physical activity benefits are well-documented for cardiometabolic outcomes, evidence for histological outcomes and fibrosis reduction is less robust 1

Pharmacological Therapy: Disease Stage-Specific Approach

For Non-Cirrhotic MASH with Significant Fibrosis (Stage F2-F3)

Resmetirom (if locally approved):

• First-line MASH-targeted therapy for patients with fibrosis stage >2, based on phase III trial demonstrating histological efficacy on both steatohepatitis and fibrosis with acceptable safety profile 1
• May also consider for patients with: advanced fibrosis, at-risk steatohepatitis with significant fibrosis (by biopsy or validated non-invasive panels), or high risk of adverse liver-related outcomes by elastography/biomarker thresholds 1
• Critical caveat: Long-term data on sustainability of benefits, individual response prediction, liver-related outcomes, and safety remain unavailable 1

Semaglutide 2.4 mg weekly (Wegovy® formulation):

• FDA-approved in August 2025 for MASH with moderate to advanced fibrosis (F2-F3) based on ESSENCE trial showing 62.9% MASH resolution and 36.8% fibrosis improvement at 72 weeks 2
• Identify candidates using non-invasive tests: VCTE 8-15 kPa, MRE 3.1-4.4 kPa, or ELF 9.2-10.5 2
• For borderline cases (VCTE 15-20 kPa, MRE 4.4-5 kPa, ELF 10.5-11.3), make individualized treatment decisions after excluding cirrhosis with confirmatory testing, imaging, or platelet count >150,000/mm³ 2
• Monitor for gastrointestinal side effects (nausea, diarrhea, constipation, vomiting), which are typically mild and transient; use dose titration to improve tolerance 2
• Watch for rare serious risks: acute kidney injury from dehydration, symptomatic gallbladder disease, pancreatitis, thyroid C-cell tumors, retinopathy progression, and lean mass loss 2

Agents NOT Recommended as MASH-Targeted Therapy

Vitamin E: Cannot be recommended despite some historical use, due to lack of robust phase III trial evidence for histological efficacy and concerns about long-term risks 1

GLP-1 receptor agonists (general class): While safe in MASH and should be used for their approved indications (type 2 diabetes, obesity) given cardiometabolic benefits, they cannot currently be recommended specifically as MASH-targeted therapies absent formal phase III histological improvement data 1

• Exception: Semaglutide 2.4 mg weekly now has specific FDA approval for MASH with F2-F3 fibrosis 2
• Substantial weight loss from GLP-1RAs may produce hepatic histological benefit, though not extensively documented 1

Pioglitazone: Safe in non-cirrhotic MASH but cannot be recommended as MASH-targeted therapy due to insufficient phase III evidence for histological efficacy 1

SGLT2 inhibitors and metformin: Insufficient evidence as MASH-targeted therapies, but safe to use for their approved indications (type 2 diabetes, heart failure, chronic kidney disease) 1

Nutraceuticals: Cannot be recommended due to insufficient evidence of effectiveness and safety 1

Management of Comorbidities

Cardiometabolic Risk Factor Optimization

• Use incretin-based therapies (semaglutide, tirzepatide) when indicated for type 2 diabetes or obesity, as these improve cardiometabolic outcomes 1
• Statins should be used according to cardiovascular risk guidelines to reduce cardiovascular events, and are safe in chronic liver disease including compensated cirrhosis 1

Alcohol Assessment

• Document detailed alcohol history using standardized tools like AUDIT-C to identify unsuspected alcohol-related liver disease and facilitate tailored advice 1
• Discourage alcohol consumption as part of lifestyle modification 1

Surgical Intervention

Bariatric surgery should be considered for non-cirrhotic MASLD patients with approved indications, as it induces long-term beneficial liver effects and is associated with type 2 diabetes remission and improved cardiometabolic risk factors 1

For compensated advanced chronic liver disease/compensated cirrhosis with approved indications, bariatric surgery can be considered but requires careful multidisciplinary evaluation including assessment for clinically significant portal hypertension 1

Special Considerations for Cirrhotic Stage

No MASH-targeted pharmacotherapy can currently be recommended for cirrhotic-stage disease 1

For patients with compensated cirrhosis:

• Adapt dietary and lifestyle recommendations to disease severity, nutritional status, and presence of sarcopenia/sarcopenic obesity 1
• Emphasize moderate weight reduction with high protein intake and physical activity to maintain muscle mass 1
• Metformin can be used with preserved renal function but avoid in decompensated cirrhosis due to lactic acidosis risk 1
• GLP-1 receptor agonists can be used in Child-Pugh class A cirrhosis for approved indications 1
• SGLT2 inhibitors can be used in Child-Pugh class A and B cirrhosis 1

Monitoring Treatment Response

For patients on semaglutide, assess response using:

• ALT reduction >17 U/L or ≥20% from baseline suggests MASH resolution 2
• CAP reduction ≥30% suggests steatosis improvement 2
• VCTE LSM reduction ≥30%, MRE LSM reduction ≥20%, or ELF reduction ≥0.5 suggests fibrosis improvement 2
• Suspect non-response if ALT or non-invasive tests worsen 2